Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275993 | 1.00 | CYP1A2 (0.31) | CYP1A2CYP2C19POLB | |
| SCHEMBL12200032 | 1.00 | CYP1A2 (0.31) | CYP1A2CYP2C19POLB | |
| SCHEMBL28928422 | 0.83 | TP53 (0.33) | CYP1A2CYP2C19POLB | |
| SCHEMBL23301101 | 0.81 | — | — | |
| SCHEMBL21857857 | 0.81 | — | — | |
| SCHEMBL28890358 | 0.80 | CYP1A2 (0.31) | CYP1A2CYP2C19POLB | |
| SCHEMBL20899842 | 0.78 | POLB (0.33) | CYP1A2CYP2C19POLB | |
| SCHEMBL20899843 | 0.78 | POLB (0.33) | CYP1A2CYP2C19POLB | |
| SCHEMBL28823992 | 0.76 | ALDH1A1 (0.34) | — | |
| SCHEMBL28823993 | 0.76 | ALDH1A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225213-B1 | TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-04-29 | — | — | EP | disclosed |
| EP-2607356-B1 | Triazole-substituted arylamide derivatives and their use as P2x3 and /or P2x2/3 purinergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2015-04-29 | — | — | EP | disclosed |
| US-20150065521-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 MODULATORS | ROCHE PALO ALTO LLC (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2607356-A1 | Triazole-substituted arylamide derivatives and their use as P2x3 and /or P2x2/3 purinergic receptor antagonists | F. Hoffmann-La Roche AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| CN-101903359-B | Triazole-substituted arylamide derivatives and their use as P2X3 and/or P2X2/3 purinergic receptor antagonists | HOFFMANN LA ROCHE | 2013-05-22 | — | — | CN | disclosed |
| US-8440708-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110245271-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC. | 2011-10-06 | — | — | US | disclosed |
| US-7989637-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2011-08-02 | — | — | US | disclosed |
| CN-101903359-A | Triazole-substituted arylamide derivatives and their use as P2X3And/or P2X2/3Use of purinergic receptor antagonists | HOFFMANN LA ROCHE | 2010-12-01 | — | — | CN | disclosed |
| EP-2225213-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| WO-2009077366-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245271-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | CYP1A2 1235/4885CYP2C19 789/4885POLB 4385/4885 |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | CYP1A2 1235/4885CYP2C19 789/4885POLB 4385/4885 |
| US-20150065521-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 MODULATORS | P2RX3, P2RX2, P2RX7 | CYP1A2 1219/4885CYP2C19 726/4885POLB 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.